ParkinsonCanadaV1, PubMed, Corpus, bibRecord, 000281

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.

Identifieur interne : 000281 ( PubMed/Corpus ); précédent : 000280; suivant : 000282

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.

Auteurs : Tiago A. Mestre ; Anthony E. Lang ; Michael S. Okun

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2016.

RBID : pubmed:26952118

English descriptors

KwdEn :
- Animals, Deep Brain Stimulation, Humans, Movement Disorders (physiopathology), Movement Disorders (therapy), Nocebo Effect, Parkinson Disease (therapy), Placebo Effect, Subthalamic Nucleus (physiology), Subthalamic Nucleus (physiopathology), Subthalamic Nucleus (surgery).
MESH :
- physiology : Subthalamic Nucleus.
- physiopathology : Movement Disorders, Subthalamic Nucleus.
- surgery : Subthalamic Nucleus.
- therapy : Movement Disorders, Parkinson Disease.
- Animals, Deep Brain Stimulation, Humans, Nocebo Effect, Placebo Effect.

Abstract

Deep brain stimulation (DBS) is a well-established treatment option for movement disorders, especially for Parkinson's disease (PD). There is a need to determine the role of expectation of benefit and the use of placebo to better understand the effects of electrode placement including the (micro)lesion effect. These factors must be understood to better interpret and attribute the therapeutic value of DBS. In this review, we critically present currently available data on the placebo, nocebo, lessebo, and lesion effects in the context of DBS. We provide a discussion of strategies that have the potential for controlling these effects in the setting of future DBS trials. We conclude that there is a need to standardize definitions for nocebo and (micro)lesion effects and that there are intrinsic limitations in defining the effect of expectation of benefit in DBS. These issues will be challenging to overcome especially with current technology and available study designs. New stimulation paradigms, better study designs, and the use of adaptive closed-loop DBS devices may facilitate a more accurate assessment of the placebo, nocebo, and lessebo effects in future DBS trials.

DOI: 10.1002/mds.26500
PubMed: 26952118

Links to Exploration step

pubmed:26952118

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.</title>
<author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name>
<affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
<affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name>
<affiliation><nlm:affiliation>Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida Health, Gainesville, Florida, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26952118</idno>
<idno type="pmid">26952118</idno>
<idno type="doi">10.1002/mds.26500</idno>
<idno type="wicri:Area/PubMed/Corpus">000281</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000281</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.</title>
<author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name>
<affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
<affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Okun, Michael S" sort="Okun, Michael S" uniqKey="Okun M" first="Michael S" last="Okun">Michael S. Okun</name>
<affiliation><nlm:affiliation>Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida Health, Gainesville, Florida, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Deep Brain Stimulation</term>
<term>Humans</term>
<term>Movement Disorders (physiopathology)</term>
<term>Movement Disorders (therapy)</term>
<term>Nocebo Effect</term>
<term>Parkinson Disease (therapy)</term>
<term>Placebo Effect</term>
<term>Subthalamic Nucleus (physiology)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
<term>Subthalamic Nucleus (surgery)</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Movement Disorders</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Deep Brain Stimulation</term>
<term>Humans</term>
<term>Nocebo Effect</term>
<term>Placebo Effect</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Deep brain stimulation (DBS) is a well-established treatment option for movement disorders, especially for Parkinson's disease (PD). There is a need to determine the role of expectation of benefit and the use of placebo to better understand the effects of electrode placement including the (micro)lesion effect. These factors must be understood to better interpret and attribute the therapeutic value of DBS. In this review, we critically present currently available data on the placebo, nocebo, lessebo, and lesion effects in the context of DBS. We provide a discussion of strategies that have the potential for controlling these effects in the setting of future DBS trials. We conclude that there is a need to standardize definitions for nocebo and (micro)lesion effects and that there are intrinsic limitations in defining the effect of expectation of benefit in DBS. These issues will be challenging to overcome especially with current technology and available study designs. New stimulation paradigms, better study designs, and the use of adaptive closed-loop DBS devices may facilitate a more accurate assessment of the placebo, nocebo, and lessebo effects in future DBS trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26952118</PMID>
<DateCreated><Year>2016</Year>
<Month>03</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>31</Volume>
<Issue>3</Issue>
<PubDate><Year>2016</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.</ArticleTitle>
<Pagination><MedlinePgn>290-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26500</ELocationID>
<Abstract><AbstractText>Deep brain stimulation (DBS) is a well-established treatment option for movement disorders, especially for Parkinson's disease (PD). There is a need to determine the role of expectation of benefit and the use of placebo to better understand the effects of electrode placement including the (micro)lesion effect. These factors must be understood to better interpret and attribute the therapeutic value of DBS. In this review, we critically present currently available data on the placebo, nocebo, lessebo, and lesion effects in the context of DBS. We provide a discussion of strategies that have the potential for controlling these effects in the setting of future DBS trials. We conclude that there is a need to standardize definitions for nocebo and (micro)lesion effects and that there are intrinsic limitations in defining the effect of expectation of benefit in DBS. These issues will be challenging to overcome especially with current technology and available study designs. New stimulation paradigms, better study designs, and the use of adaptive closed-loop DBS devices may facilitate a more accurate assessment of the placebo, nocebo, and lessebo effects in future DBS trials.</AbstractText>
<CopyrightInformation>© 2016 International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mestre</LastName>
<ForeName>Tiago A</ForeName>
<Initials>TA</Initials>
<AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lang</LastName>
<ForeName>Anthony E</ForeName>
<Initials>AE</Initials>
<AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okun</LastName>
<ForeName>Michael S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida Health, Gainesville, Florida, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064786" MajorTopicYN="Y">Nocebo Effect</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015990" MajorTopicYN="Y">Placebo Effect</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Microlesion</Keyword>
<Keyword MajorTopicYN="N">Parkinson's disease</Keyword>
<Keyword MajorTopicYN="N">deep brain stimulation</Keyword>
<Keyword MajorTopicYN="N">essential tremor</Keyword>
<Keyword MajorTopicYN="N">lessebo</Keyword>
<Keyword MajorTopicYN="N">microelectrode recording</Keyword>
<Keyword MajorTopicYN="N">pallidotomy</Keyword>
<Keyword MajorTopicYN="N">placebo</Keyword>
<Keyword MajorTopicYN="N">subthalamotomy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>07</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>11</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>11</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>3</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26952118</ArticleId>
<ArticleId IdType="doi">10.1002/mds.26500</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000281 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:26952118
   |texte=   Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:26952118" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki